Radiopharm Theranostics Completes Phase 2b Trial Enrollment for Brain Metastases Imaging Agent
Event summary
- Radiopharm Theranostics completed enrollment in its U.S. Phase 2b imaging trial for RAD 101, targeting brain metastases diagnosis.
- Interim data showed 90% concordance with MRI, the primary endpoint.
- Full trial results expected in June 2026, with plans to advance to a Phase 3 pivotal trial.
- RAD 101 received FDA Fast Track Designation for distinguishing recurrent brain metastases from treatment effects.
The big picture
Radiopharm Theranostics is advancing its radiopharmaceutical pipeline with RAD 101, targeting a critical unmet need in brain metastases diagnosis. The high concordance rate with MRI positions the company to challenge the dominance of conventional imaging methods, potentially reshaping diagnostic protocols in oncology. With over 300,000 annual cases of cerebral metastases in the U.S., the market opportunity is substantial, provided the company can navigate regulatory and operational hurdles.
What we're watching
- Regulatory Pathway
- Whether the FDA will expedite approval for RAD 101 given its Fast Track Designation and strong interim data.
- Market Potential
- The pace at which RAD 101 could capture market share in diagnosing brain metastases, given the limitations of current MRI technology.
- Execution Risk
- How Radiopharm Theranostics will manage the transition from Phase 2b to Phase 3 trials, including recruitment and data consistency.